0001714899-21-000117.txt : 20211230 0001714899-21-000117.hdr.sgml : 20211230 20211230215944 ACCESSION NUMBER: 0001714899-21-000117 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211228 FILED AS OF DATE: 20211230 DATE AS OF CHANGE: 20211230 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tessier-Lavigne Marc CENTRAL INDEX KEY: 0001437435 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 211534381 MAIL ADDRESS: STREET 1: 1 DNA WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 wf-form4_164091956763788.xml FORM 4 X0306 4 2021-12-28 0 0001714899 Denali Therapeutics Inc. DNLI 0001437435 Tessier-Lavigne Marc C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2021-10-04 5 G 0 E 300000 0 D 2244370 D Common Stock 2021-10-04 5 G 0 E 100000 0 A 100000 I The Tessier-Lavigne/Hynes Irrevocable Trust 1 Common Stock 2021-12-28 4 S 0 3732 44.37 D 96268 I The Tessier-Lavigne/Hynes Irrevocable Trust 1 Common Stock 2021-12-29 4 S 0 10700 43.88 D 85568 I The Tessier-Lavigne/Hynes Irrevocable Trust 1 Common Stock 2021-12-30 4 S 0 3343 45.13 D 82225 I The Tessier-Lavigne/Hynes Irrevocable Trust 1 Common Stock 2021-12-30 4 S 0 3377 45.59 D 78848 I The Tessier-Lavigne/Hynes Irrevocable Trust 1 Common Stock 2021-10-04 5 G 0 E 100000 0 A 100000 I The Tessier-Lavigne/Hynes Irrevocable Trust 2 Common Stock 2021-12-28 4 S 0 3602 44.38 D 96398 I The Tessier-Lavigne/Hynes Irrevocable Trust 2 Common Stock 2021-12-29 4 S 0 10700 43.87 D 85698 I The Tessier-Lavigne/Hynes Irrevocable Trust 2 Common Stock 2021-12-30 4 S 0 5625 45.31 D 80073 I The Tessier-Lavigne/Hynes Irrevocable Trust 2 Common Stock 2021-12-30 4 S 0 900 45.71 D 79173 I The Tessier-Lavigne/Hynes Irrevocable Trust 2 Common Stock 2021-10-04 5 G 0 E 100000 0 A 100000 I The Tessier-Lavigne/Hynes Irrevocable Trust 3 Common Stock 2021-12-28 4 S 0 3646 44.37 D 96354 I The Tessier-Lavigne/Hynes Irrevocable Trust 3 Common Stock 2021-12-29 4 S 0 10704 43.88 D 85650 I The Tessier-Lavigne/Hynes Irrevocable Trust 3 Common Stock 2021-12-30 4 S 0 6002 45.31 D 79648 I The Tessier-Lavigne/Hynes Irrevocable Trust 3 Common Stock 2021-12-30 4 S 0 800 45.72 D 78848 I The Tessier-Lavigne/Hynes Irrevocable Trust 3 This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. Includes 2,074 restricted stock units. The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.19 to $44.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.50 to $44.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.42 to $45.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.42 to $45.81 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.19 to $44.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.51 to $44.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.65 to $45.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.66 to $45.77 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.18 to $44.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.50 to $44.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.65 to $45.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.67 to $45.80 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. /s/ Tyler Nielsen, by power of attorney 2021-12-30